Infinity Pharmaceuticals Inc. (NASDAQ:INFI) finished Wednesday with a subtraction of $0.0 to close at $0.09, an upside of 2.27 percent. An average of 2,519,260 shares of common stock have been traded in the last five days. There was a fall of -$0.0200 in the past week, and it reached a new high 1 time over the past 12 months. The last 20 days have seen an average of 8,131,450 shares traded, while the 50-day average volume stands at 4,028,940.
INFI stock has decreased by -33.82% in the last month. The company shares reached their 1-month lowest point of $0.0850 on 08/16/23. With the stock rallying to its 52-week high on 01/18/23, shares of the company touched a low of $0.09 and a high of $1.76 in 52 weeks. It has reached a new high 7 times so far this year and lost -83.78% or -$0.4650 in price. In spite of this, the price is down -94.89% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Valuation Metrics
Infinity Pharmaceuticals Inc. (INFI) stock’s beta is 1.41. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 3.23.
Financial Health
The quick ratio of Infinity Pharmaceuticals Inc. for the three months ended March 30 was 1.70, and the current ratio was 1.70, indicating that the company is able to meet its debt obligations. Infinity Pharmaceuticals Inc.’s EBITDA margin for the year ending March 30 is -1711.76%. Its gross profit as reported stood at $47.44 million compared to revenue of $2.59 million.
Earnings Surprise
In the quarter under review, the net income was down than the previous quarter. The company posted a net income of -$9.96 million in the quarter, while revenues were shrunk -20.38%. The analyst consensus anticipated Infinity Pharmaceuticals Inc.’s latest quarter earnings to come in at -$0.1 per share, but it turned out to be -$0.12, a -20.00% surprise. For the quarter, EBITDA amounted to -$10.01 million. Shareholders own equity worth $90.76 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at Infinity Pharmaceuticals Inc. (INFI) price momentum. RSI 9-day as of the close on 23 August was 37.32%, suggesting the stock is Neutral, with historical volatility in this time frame at 155.35%.
As of today, INFI’s price is $0.0945 -18.18% or -$0.0200 from its 5-day moving average. INFI is currently trading -35.71% lower than its 20-day SMA and -50.00% lower than its 100-day SMA. However, the stock’s current price level is -49.66% below the SMA50 and -92.62% below the SMA200.
The stochastic %K and %D were 6.91% and 9.48%, respectively, and the average true range (ATR) was 0.0186. With the 14-day stochastic at 4.94% and the average true range at 0.0204, the RSI (14) stands at 37.85%. The stock has reached -0.0046 on the 9-day MACD Oscillator while the 14-day reading was at -0.0104.
Analyst Ratings
H.C. Wainwright launched coverage on Infinity Pharmaceuticals Inc. (NASDAQ: INFI) in its analyst report released on October 18, 2021. The firm assigned the stock a Buy rating. The consensus rating for Infinity Pharmaceuticals Inc. (INFI) among analysts is Hold. According to current brokerage recommendations, 0 brokerage firms advise that investors sell INFI, while 1 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 0 others rate it as a “buy”.
What is INFI’s price target for the next 12 months?
Analysts predict a range of price targets between $0.30 and $0.30, with a median target of $0.30. Taking a look at these predictions, the average price target given by analysts for Infinity Pharmaceuticals Inc. (INFI) stock is $0.30.
